Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 643-652
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.643
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.643
Table 1 Studies of immunoscore role in patients receiving adjuvant chemotherapy
Ref. | CRC stage | ACT | IS predictive role (DFS) |
Church et al[27] | III | mFOLFOX, 3 vs 6 months | 3-yr DFS: 3 months IS high/IS low HR = 1.80 (95%CI: 1.25-2.60); 6 months IS high/IS low HR = 2.00 (95%CI: 1.38-2.92) |
Pagès et al[28] | III | mFOLFOX, 3 vs 6 months | DFS: IS Int + high: HR = 0.53; 95%CI: 0.37-0.75; P = 0.0004; IS low: HR = 0.84, P = 0.269 |
Mlecnik et al[29] | II, III | 5-FU | IS 2-3 III stage: HR = 2.69 (1.02-7.11) P = 0.038; IS 2-3 II: HR = 1.47 (0.35-6.18) P: Non-significant; IS4/IS0-1: No effect of ACT was detected |
Pagès et al[30] | III | mFOLFOX, 3 vs 6 months | 3-yr DFS: T1-3, N1, IS high 91.4% vs 80.9%, P = 0.01; T1-3, N1, IS low 77.5% vs 74.5%, P = 0.56; T4/N2 IS high 72.0% vs 56.0%, P = 0.006; T4/N2 IS low 58.2% vs 52.6%, P = 0.2 |
- Citation: Kuznetsova O, Fedyanin M, Zavalishina L, Moskvina L, Kuznetsova O, Lebedeva A, Tryakin A, Kireeva G, Borshchev G, Tjulandin S, Ignatova E. Prognostic and predictive role of immune microenvironment in colorectal cancer. World J Gastrointest Oncol 2024; 16(3): 643-652
- URL: https://www.wjgnet.com/1948-5204/full/v16/i3/643.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i3.643